The Therapeutic Effect of a Multistrain Probiotic on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study
Backgrounds. Recent studies suggest that diarrhea-predominant irritable bowel syndrome (IBS) is associated with intestinal bacterial microflora, colonic inflammation, and small intestinal bacterial overgrowth (SIBO). The purpose of this study was to evaluate the effect of a multistrain probiotic int...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2018/8791916 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850168578718826496 |
|---|---|
| author | Seok-Hoon Lee Nam-Seok Joo Kwang-Min Kim Kyu-Nam Kim |
| author_facet | Seok-Hoon Lee Nam-Seok Joo Kwang-Min Kim Kyu-Nam Kim |
| author_sort | Seok-Hoon Lee |
| collection | DOAJ |
| description | Backgrounds. Recent studies suggest that diarrhea-predominant irritable bowel syndrome (IBS) is associated with intestinal bacterial microflora, colonic inflammation, and small intestinal bacterial overgrowth (SIBO). The purpose of this study was to evaluate the effect of a multistrain probiotic intake on these associated factors in patients with diarrhea-predominant IBS. Methods. The recruited volunteers were adults who were diagnosed with diarrhea-predominant IBS according to the Rome III criteria. After 8 weeks of probiotic ingestion, changes in gastrointestinal symptoms, fecal microbiome, SIBO, and fecal calprotectin were determined. Results. There was an increase in beneficial bacteria (41.2 ± 16.8% vs. 53.7 ± 15.3%, P=0.018) and a decrease in harmful bacteria (13.0 ± 13.9% vs. 4.7 ± 4.0%, P=0.010) in the microbial stool analysis. The SIBO prevalence also decreased at the end of treatment. However, the average levels of fecal calprotectin showed a decreasing tendency, without reaching statistical significance (364.4 ± 729.1 mg/kg vs. 200.9 ± 347.6 mg/kg, P=0.375). Conclusion. Treatment with a multistrain probiotic for 8 weeks led to significant increases in beneficial bacteria in the gut as well as the improvement of gastrointestinal symptoms. This study is registered at the Clinical Research Information Service (KCT0002906). |
| format | Article |
| id | doaj-art-a7da5819d00646b79a0983e64a8f3e1a |
| institution | OA Journals |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-a7da5819d00646b79a0983e64a8f3e1a2025-08-20T02:20:56ZengWileyGastroenterology Research and Practice1687-61211687-630X2018-01-01201810.1155/2018/87919168791916The Therapeutic Effect of a Multistrain Probiotic on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot StudySeok-Hoon Lee0Nam-Seok Joo1Kwang-Min Kim2Kyu-Nam Kim3Department of Family Practice and Community Health, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Family Practice and Community Health, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Family Practice and Community Health, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Family Practice and Community Health, Ajou University School of Medicine, Suwon, Republic of KoreaBackgrounds. Recent studies suggest that diarrhea-predominant irritable bowel syndrome (IBS) is associated with intestinal bacterial microflora, colonic inflammation, and small intestinal bacterial overgrowth (SIBO). The purpose of this study was to evaluate the effect of a multistrain probiotic intake on these associated factors in patients with diarrhea-predominant IBS. Methods. The recruited volunteers were adults who were diagnosed with diarrhea-predominant IBS according to the Rome III criteria. After 8 weeks of probiotic ingestion, changes in gastrointestinal symptoms, fecal microbiome, SIBO, and fecal calprotectin were determined. Results. There was an increase in beneficial bacteria (41.2 ± 16.8% vs. 53.7 ± 15.3%, P=0.018) and a decrease in harmful bacteria (13.0 ± 13.9% vs. 4.7 ± 4.0%, P=0.010) in the microbial stool analysis. The SIBO prevalence also decreased at the end of treatment. However, the average levels of fecal calprotectin showed a decreasing tendency, without reaching statistical significance (364.4 ± 729.1 mg/kg vs. 200.9 ± 347.6 mg/kg, P=0.375). Conclusion. Treatment with a multistrain probiotic for 8 weeks led to significant increases in beneficial bacteria in the gut as well as the improvement of gastrointestinal symptoms. This study is registered at the Clinical Research Information Service (KCT0002906).http://dx.doi.org/10.1155/2018/8791916 |
| spellingShingle | Seok-Hoon Lee Nam-Seok Joo Kwang-Min Kim Kyu-Nam Kim The Therapeutic Effect of a Multistrain Probiotic on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study Gastroenterology Research and Practice |
| title | The Therapeutic Effect of a Multistrain Probiotic on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study |
| title_full | The Therapeutic Effect of a Multistrain Probiotic on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study |
| title_fullStr | The Therapeutic Effect of a Multistrain Probiotic on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study |
| title_full_unstemmed | The Therapeutic Effect of a Multistrain Probiotic on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study |
| title_short | The Therapeutic Effect of a Multistrain Probiotic on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study |
| title_sort | therapeutic effect of a multistrain probiotic on diarrhea predominant irritable bowel syndrome a pilot study |
| url | http://dx.doi.org/10.1155/2018/8791916 |
| work_keys_str_mv | AT seokhoonlee thetherapeuticeffectofamultistrainprobioticondiarrheapredominantirritablebowelsyndromeapilotstudy AT namseokjoo thetherapeuticeffectofamultistrainprobioticondiarrheapredominantirritablebowelsyndromeapilotstudy AT kwangminkim thetherapeuticeffectofamultistrainprobioticondiarrheapredominantirritablebowelsyndromeapilotstudy AT kyunamkim thetherapeuticeffectofamultistrainprobioticondiarrheapredominantirritablebowelsyndromeapilotstudy AT seokhoonlee therapeuticeffectofamultistrainprobioticondiarrheapredominantirritablebowelsyndromeapilotstudy AT namseokjoo therapeuticeffectofamultistrainprobioticondiarrheapredominantirritablebowelsyndromeapilotstudy AT kwangminkim therapeuticeffectofamultistrainprobioticondiarrheapredominantirritablebowelsyndromeapilotstudy AT kyunamkim therapeuticeffectofamultistrainprobioticondiarrheapredominantirritablebowelsyndromeapilotstudy |